Exhibit 99
Contact: | Claire M. Gulmi | |
Executive Vice President and | ||
Chief Financial Officer | ||
(615) 665-1283 | ||
AMSURG ANNOUNCES SECOND-QUARTER FINANCIAL RESULTS
———————————
REPORTS DILUTED EPS OF $0.80 AND ADJUSTED DILUTED EPS OF $1.10
NASHVILLE, Tenn. ─ (August 2, 2016) ─ AMSURG Corp. (NASDAQ: AMSG) today announced financial results for the second quarter and six months ended June 30, 2016. The Company’s results for the quarter, compared with the second quarter of 2015, included:
• | Net revenues of $758.5 million, up 18% from $642.0 million for the second quarter of 2015; |
• | An increase of 39% in net earnings attributable to AMSURG common shareholders to $43.8 million; |
• | A 23% increase in net earnings attributable to AMSURG common shareholders to $0.80 per diluted share; |
• | An increase of 27% in adjusted net earnings to $63.1 million; |
• | 13% growth in adjusted net earnings to $1.10 per diluted share, on a 12% increase in diluted shares outstanding, if converted, primarily due the Company’s December 2015 public offering of common stock; and |
• | Adjusted EBITDA of $149.2 million, up 17%. |
See page 6 for a reconciliation of all GAAP and non-GAAP financial results.
“We are pleased with AMSURG’s operating and financial performance for the second quarter, highlighted by our significant profitable growth,” commented Christopher A. Holden, President and Chief Executive Officer of AMSURG. “Our net revenues again reflected meaningful organic growth, with a 4.2% increase in same center revenues for our Ambulatory Services division and a 5.5% increase in same contract revenue for our Physician Services division. We also continued to expand and strengthen our market presence for both divisions and positioned AMSURG for future growth through the completion of nine acquisitions during the quarter. Finally, we executed a definitive agreement for a transformative merger with Envision Healthcare. On completion, this merger will create a national provider of a broad continuum of clinical network solutions, including multiple outsourced physician specialties, such as emergency, hospitalist, anesthesia, radiology and children’s services, as well as solutions for ambulatory surgery, post-acute care and medical transportation. We continue to expect to complete the merger by the end of 2016, subject to regulatory approvals, approval by Envision and AMSURG shareholders and the satisfaction or waiver of other customary closing conditions.
“During the second quarter, Ambulatory Services acquired four ambulatory surgery centers. Physician Services completed five acquisitions during the second quarter, three of which were closed on June 30, 2016. The Physician Services transactions were comprised of a radiology practice and four anesthesia practices, including a multi-state anesthesia practice focused on serving ASCs. The transactions expanded Physician Services’ presence in existing markets and established the division’s initial presence in Illinois. We continue to evaluate additional potential acquisitions in our strong pipeline, including opportunities for Ambulatory Services and across all our Physician Services specialties. In the first half of 2016, we deployed nearly $300 million of capital for acquisitions, which we expect to increase to approximately $400 million for the full year. Subsequent to the end of the second quarter, Ambulatory Services has completed the acquisition of three additional ASCs.
AMSG Reports Second-Quarter Results | ||
Page 2 | ||
August 2, 2016 | ||
“During the second quarter, the timing of our acquisitions was later than anticipated, which affected the quarter’s revenue and will affect our full-year revenue performance. In addition, our Physician Services new contract signings are on target to meet or exceed our expectations for the year, however, the start dates for these new contracts are later in the year than assumed when preparing our revenue guidance. While the timing of the new contract starts will affect revenue growth for 2016, it will have little impact on net earnings.”
Ambulatory Services
Net revenues for the second quarter of 2016 were $319.7 million, a 2.8% increase from $311.0 million for the second quarter of 2015. The growth in net revenue was impacted by the deconsolidation of nine ASCs during the 12 months ended June 30, 2016, which contributed incremental revenues of $18.4 million for the second quarter of 2015. The 4.2% increase in same center revenues for the second quarter of 2016 compared with the second quarter of 2015 was comprised of a 3.3% increase in procedures and a 0.9% increase in net revenue per procedure. Adjusted EBITDA was $61.7 million for the second quarter, up 2.4% from $60.3 million for the second quarter last year.
Ambulatory Services operated 258 ASCs and one surgical hospital at June 30, 2016. In addition to acquiring four ASCs during the quarter, Ambulatory Services disposed of two ASCs and deconsolidated one ASC, which was contributed to a new joint venture with a hospital. The division had four ASCs under letter of intent at the end of the second quarter of 2016, three of which have now been purchased, and one ASC was under development, which is expected to open in the third quarter of 2016.
Physician Services
Net revenues for Physician Services increased 33% to $438.8 million from $331.0 million for the second quarter of 2015. Adjusted EBITDA was $87.5 million for the quarter, up 29% from $67.7 million for the second quarter of 2015, and adjusted EBITDA margin was 19.9% compared with 20.4%.
The comparable-quarter growth in Physician Services revenues was comprised of an increase of 4.5% in same-contract revenues, 0.6% in net new contract revenues and 27.5% in acquisition revenues. Same-contract growth in net revenues totaled 5.5% for the second quarter of 2016, which included a 5.1% increase in patient encounters per day and a 0.4% increase in net revenue per patient encounter.
Liquidity
At June 30, 2016, AMSURG had cash and cash equivalents of $74.1 million and availability under its $500 million revolving credit facility of $100 million. Net cash flows from operations, less distributions to noncontrolling interests, were $54.5 million for the second quarter. The Company’s ratio of total debt at the end of the second quarter to trailing 12 months EBITDA as calculated under the Company’s credit agreement was 4.2.
Merger Update
AMSURG expects that the preliminary joint proxy statement/prospectus related to its previously announced merger with Envision Healthcare Holdings, Inc. (NYSE: EVHC) will be filed with the U.S. Securities and Exchange Commission on Thursday, August 4, 2016, by the new registrant “New Amethyst Corp.”
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 3 | ||
August 2, 2016 | ||
Guidance
AMSURG today adjusted its 2016 financial guidance for net revenues as a result of the revised timing of acquisitions and new contract signings in 2016. The Company also provided financial guidance for the third quarter of 2016. The Company’s financial and operating guidance is as follows:
• | Revenues of $3.05 billion to $3.09 billion for 2016, compared with $3.09 billion to $3.13 billion previously; |
• | A same-center revenue increase of 4% to 6% for Ambulatory Services for 2016 and same-contract revenue growth of 4% to 6% in Physician Services; |
• | Adjusted EBITDA of $592 million to $601 million for 2016; |
• | Adjusted EPS of $4.28 to $4.35 for 2016; and |
• | For the third quarter of 2016, adjusted EPS of $1.10 to $1.13. |
Non-GAAP Adjusted EBITDA guidance for the full year of 2016 excludes interest expense, income taxes, depreciation, amortization, share-based compensation, transaction costs, changes in contingent purchase price consideration, gain or loss on deconsolidations and discontinued operations. Non-GAAP Adjusted EPS guidance for the third quarter and full year of 2016 exclude acquisition-related transaction costs, acquisition-related amortization expense, gains and losses on future deconsolidation transactions and share-based compensation expense, net of the tax impact thereon. The exact amount of such exclusions are not currently determinable but may be significant and may vary significantly from period to period (see page 6 for a reconciliation of all GAAP and non-GAAP financial results).
Conference Call
AMSURG Corp. will hold a conference call to discuss this release today, August 2, 2016, at 5:00 p.m. Eastern time. Investors will have the opportunity to listen to the conference call over the Internet by going to www.amsurg.com and clicking “Investors” at least 15 minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available at these sites shortly after the call and continue for 30 days.
Safe Harbor
This press release contains forward-looking statements, including the Company’s financial and operating guidance for the first quarter and full year of 2016. These statements, which have been included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties. Investors are hereby cautioned that these statements may be affected by important factors, including, but not limited to, the following risks: we may face challenges managing our Physician Services Division as a new business and may not realize anticipated benefits; we may become subject to investigations by federal and state entities and unpredictable impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010; there may be governmental or commercial health changes designed to reduce the number of surgical procedures; we may fail to comply with applicable laws and regulations including the federal Anti-Kickback statue and similar state laws; we may not be able to successfully maintain effective internal controls over financial reporting; we may not be able to implement our business strategy, manage the growth in our business, and integrate acquired businesses; the attention of management may be diverted by the process of making new acquisitions; the risks associated with our ability to consummate the business combination with Envision and the timing of the closing of the business combination; the ability to successfully integrate our and Envision’s operations and employees; the ability to realize the anticipated benefits and synergies of the business combination with Envision; the potential impact of the announcement of the business combination or consummation of the transaction on relationships, including with our employees, customers and competitors; our substantial indebtedness and restrictions in our debt instruments could adversely affect our business or our ability to implement our growth strategy, or limit our ability to react to changes in the economy or our industry; we may not generate sufficient cash to service our indebtedness, including any future indebtedness; restricted covenants in our indenture
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 4 | ||
August 2, 2016 | ||
documents may restrict our business strategies or could result in an acceleration of our debt; regulatory changes may obligate us to buy out interests of physicians who are minority owners of our surgery centers; we may not be able to successfully maintain our information systems and processes, implement new systems and processes, and maintain the security of those systems and processes; we may fail to effectively and timely transition to the ICD-10 coding system; we may fail to effectively manage and implement security measures protecting our information technology systems to protect confidential data; our disaster recovery systems or management continuity plans may be disrupted; we may face shortages or quality control issues of products, equipment, and medical supplies that could adversely affect our operations and profitability; enforcement authorities may conclude that our market share in any particular market is too concentrated or our clients’ commercial payor contract negotiating practices are illegal; we may be subject to litigation and investigations and liability claims for damages and other expenses not covered by insurance; we may be required to write-off a portion of our intangible assets; payments from third-party payors, including government healthcare programs, may decrease or not increase as our costs increase; there may be adverse developments affecting the medical practices of our physician partners; we may not be able to maintain favorable relations with our physician partners; our physician partners may fail to perform on their pro rata share of any indebtedness or lease agreements; we may not be able to grow our ambulatory services revenue by increasing procedure volume while maintaining operating margins and profitability at our existing surgery centers; we may not be able to compete for physician partners, managed care contracts, patients and strategic relationships; adverse weather and other factors beyond our control may affect our business; our legal responsibility to minority owners of our surgery centers may conflict with our interests and prevent us from acting solely in our best interests; we may be adversely impacted by changes in patient volume and patient mix; several client relationships generate a significant portion of our physician services revenues; our physician services contracts may be cancelled or not renewed or we may not be able to enter into additional contracts under terms acceptable to us; reimbursement rates, revenue and profit margin under our fee-for-service physician services payor contracts may decrease; we may not be able to timely or accurately bill for services; laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease; we may not be able to enroll our physician services providers in the Medicare and Medicaid programs on a timely basis; our strategic partnerships with healthcare providers may not be successful; our segments of the market for medical services have a high level of competition; we may not be able to successfully recruit and retain physicians, nurses and other clinical providers; we may not be able to accurately assess the costs we will incur under new contracts; our margins may be negatively impacted by cross-selling to existing clients or selling bundled services to new clients; we may not be able to enforce non-compete agreements with our physicians and other clinical employees in some jurisdictions; there may be unfavorable changes in regulatory, economic and other conditions in the states where we operate; legislative or regulatory action may make our captive insurance company arrangement less feasible or otherwise reduce our profitability; our reserves with respect to our losses covered under our insurance programs may not be sufficient; and the other risk factors are described in AMSURG’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as updated by other filings with the Securities and Exchange Commission. Consequently, actual results, performance or developments may differ materially from the forward-looking statements included above. AMSURG disclaims any intent or obligation to update these forward-looking statements.
About AMSURG
AMSURG’s Ambulatory Services Division acquires, develops and operates ambulatory surgery centers in partnership with physicians throughout the U.S. AMSURG’s Physician Services Division, Sheridan, provides outsourced physician services in multiple specialties to hospitals, ASCs and other healthcare facilities throughout the U.S., primarily in the areas of anesthesiology, children’s services, emergency medicine and radiology. Through these businesses as of June 30, 2016, AMSURG owned and operated 258 ASCs and one surgical hospital in 34 states and the District of Columbia and provided physician services to more than 530 healthcare facilities in 32 states. AMSURG has partnerships with, or employs, over 6,000 physicians and other healthcare professionals in 40 states and the District of Columbia.
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 5 | ||
August 2, 2016 | ||
AMSURG CORP. Unaudited Selected Consolidated Financial and Operating Data (In thousands, except earnings per share) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
Statement of Earnings Data: | 2016 | 2015 | 2016 | 2015 | |||||||||||
Revenues | $ | 859,832 | $ | 707,733 | $ | 1,678,118 | $ | 1,345,930 | |||||||
Provision for uncollectibles | (101,333 | ) | (65,783 | ) | (194,941 | ) | (133,535 | ) | |||||||
Net revenue | 758,499 | 641,950 | 1,483,177 | 1,212,395 | |||||||||||
Operating expenses: | |||||||||||||||
Salaries and benefits | 404,011 | 320,396 | 813,850 | 622,575 | |||||||||||
Supply cost | 49,703 | 45,790 | 96,666 | 88,374 | |||||||||||
Other operating expenses | 111,145 | 105,002 | 218,827 | 195,572 | |||||||||||
Transaction costs | 5,135 | 1,982 | 6,525 | 3,453 | |||||||||||
Depreciation and amortization | 30,054 | 23,612 | 59,126 | 46,430 | |||||||||||
Total operating expenses | 600,048 | 496,782 | 1,194,994 | 956,404 | |||||||||||
Net gain (loss) on disposals and deconsolidations | 2,595 | (3,035 | ) | 2,595 | (3,258 | ) | |||||||||
Equity in earnings of unconsolidated affiliates | 7,351 | 3,989 | 13,930 | 6,640 | |||||||||||
Operating income | 168,397 | 146,122 | 304,708 | 259,373 | |||||||||||
Interest expense, net | 31,913 | 30,182 | 62,723 | 60,429 | |||||||||||
Earnings before income taxes | 136,484 | 115,940 | 241,985 | 198,944 | |||||||||||
Income tax expense | 33,365 | 25,193 | 54,162 | 39,442 | |||||||||||
Net earnings | 103,119 | 90,747 | 187,823 | 159,502 | |||||||||||
Less net earnings attributable to noncontrolling interests | 57,050 | 57,072 | 110,891 | 104,789 | |||||||||||
Net earnings attributable to AmSurg Corp. shareholders | 46,069 | 33,675 | 76,932 | 54,713 | |||||||||||
Preferred stock dividends | (2,264 | ) | (2,264 | ) | (4,528 | ) | (4,528 | ) | |||||||
Net earnings attributable to AmSurg Corp. common shareholders | $ | 43,805 | $ | 31,411 | $ | 72,404 | $ | 50,185 | |||||||
Net earnings per share attributable to common shareholders: | |||||||||||||||
Basic | $ | 0.82 | $ | 0.66 | $ | 1.35 | $ | 1.05 | |||||||
Diluted | $ | 0.80 | $ | 0.65 | $ | 1.34 | $ | 1.05 | |||||||
Weighted average number of shares and share equivalents outstanding: | |||||||||||||||
Basic | 53,739 | 47,678 | 53,702 | 47,625 | |||||||||||
Diluted | 57,327 | 48,099 | 57,229 | 48,002 | |||||||||||
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 6 | ||
August 2, 2016 | ||
AMSURG CORP. Unaudited Selected Consolidated Financial and Operating Data, continued (In thousands, except earnings per share) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||
Reconciliation of net earnings to Adjusted net earnings (1): | |||||||||||||||
Net earnings attributable to AmSurg Corp. shareholders | $ | 46,069 | $ | 33,675 | $ | 76,932 | $ | 54,713 | |||||||
Amortization of purchased intangibles | 18,189 | 12,490 | 35,884 | 24,912 | |||||||||||
Share-based compensation | 7,900 | 3,883 | 15,068 | 7,592 | |||||||||||
Transaction costs | 5,135 | 1,982 | 6,525 | 3,453 | |||||||||||
Net (gain) loss on disposals and deconsolidations | (2,595 | ) | 3,035 | (2,595 | ) | 3,258 | |||||||||
Net change in fair value of contingent consideration | (2,598 | ) | 6,410 | (2,598 | ) | 6,410 | |||||||||
Total pre-tax adjustments | 26,031 | 27,800 | 52,284 | 45,625 | |||||||||||
Tax effect | 8,952 | 11,593 | 19,453 | 18,723 | |||||||||||
Total adjustments, net | 17,079 | 16,207 | 32,831 | 26,902 | |||||||||||
Adjusted net earnings | $ | 63,148 | $ | 49,882 | $ | 109,763 | $ | 81,615 | |||||||
Basic shares outstanding | 53,739 | 47,678 | 53,702 | 47,625 | |||||||||||
Effect of dilutive securities, options and non-vested shares | 3,588 | 3,550 | 3,527 | 3,518 | |||||||||||
Diluted shares outstanding, if converted | 57,327 | 51,228 | 57,229 | 51,143 | |||||||||||
Adjusted earnings per share | $ | 1.10 | $ | 0.97 | $ | 1.92 | $ | 1.60 | |||||||
Reconciliation of net earnings to Adjusted EBITDA (2): | |||||||||||||||
Net earnings attributable to AmSurg Corp. shareholders | $ | 46,069 | $ | 33,675 | $ | 76,932 | $ | 54,713 | |||||||
Interest expense, net | 31,913 | 30,182 | 62,723 | 60,429 | |||||||||||
Income tax expense | 33,365 | 25,193 | 54,162 | 39,442 | |||||||||||
Depreciation and amortization | 30,054 | 23,612 | 59,126 | 46,430 | |||||||||||
EBITDA | 141,401 | 112,662 | 252,943 | 201,014 | |||||||||||
Adjustments: | |||||||||||||||
Share-based compensation | 7,900 | 3,883 | 15,068 | 7,592 | |||||||||||
Transaction costs | 5,135 | 1,982 | 6,525 | 3,453 | |||||||||||
Net (gain) loss on disposals and deconsolidations | (2,595 | ) | 3,035 | (2,595 | ) | 3,258 | |||||||||
Net change in fair value of contingent consideration | (2,598 | ) | 6,410 | (2,598 | ) | 6,410 | |||||||||
Total adjustments | 7,842 | 15,310 | 16,400 | 20,713 | |||||||||||
Adjusted EBITDA | $ | 149,243 | $ | 127,972 | $ | 269,343 | $ | 221,727 | |||||||
Segment Information: | |||||||||||||||
Ambulatory Services Adjusted EBITDA | $ | 61,746 | $ | 60,304 | $ | 115,372 | $ | 107,612 | |||||||
Physician Services Adjusted EBITDA | 87,497 | 67,668 | 153,971 | 114,115 | |||||||||||
Adjusted EBITDA | $ | 149,243 | $ | 127,972 | $ | 269,343 | $ | 221,727 | |||||||
Net Revenue by Segment: | |||||||||||||||
Ambulatory Services | $ | 319,747 | $ | 310,991 | $ | 626,881 | $ | 594,901 | |||||||
Physician Services | 438,752 | 330,959 | 856,296 | 617,494 | |||||||||||
Total net revenue | $ | 758,499 | $ | 641,950 | $ | 1,483,177 | $ | 1,212,395 | |||||||
See footnotes on page 10
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 7 | ||
August 2, 2016 | ||
AMSURG CORP. Unaudited Selected Consolidated Financial and Operating Data, continued | |||||||||||||||
Operating Data- Ambulatory Services: | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||
Procedures performed during the period at consolidated centers | 436,940 | 441,302 | 853,524 | 845,821 | |||||||||||
Centers in operation, end of period (consolidated) | 236 | 239 | 236 | 239 | |||||||||||
Centers in operation, end of period (unconsolidated) | 22 | 11 | 22 | 11 | |||||||||||
Average number of continuing centers in operation (consolidated) | 237 | 238 | 236 | 237 | |||||||||||
New centers added, during period | 4 | 2 | 4 | 4 | |||||||||||
Centers merged into existing centers, during period | — | — | 1 | — | |||||||||||
Centers discontinued, during period | 2 | — | 2 | — | |||||||||||
Centers under development, end of period | 1 | 2 | 1 | 2 | |||||||||||
Centers under letter of intent, end of period | 4 | 6 | 4 | 6 | |||||||||||
Average revenue per consolidated center (in thousands) | $ | 1,352 | $ | 1,308 | $ | 2,655 | $ | 2,515 | |||||||
Same center revenues increase (consolidated) | 4.2 | % | 5.1 | % | 6.6 | % | 4.4 | % | |||||||
Surgical hospitals in operation, end of period (unconsolidated) | 1 | — | 1 | — | |||||||||||
Operating Data- Physician Services: | |||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||
Contribution to Net Revenue Growth: | |||||||||||
Same contract | 4.5 | % | 10.9 | % | 7.0 | % | 8.1 | % | |||
New contract | 0.6 | 1.6 | 0.9 | 2.0 | |||||||
Acquired contract and other | 27.5 | 11.8 | 30.8 | 9.3 | |||||||
Total net revenue growth | 32.6 | % | 24.3 | % | 38.7 | % | 19.4 | % | |||
Same contract revenue growth | 5.5 | % | 14.3 | % | 8.4 | % | 10.5 | % | |||
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 8 | ||
August 2, 2016 | ||
AMSURG CORP. Unaudited Selected Consolidated Financial and Operating Data, continued (In thousands) | |||||||
June 30, | December 31, | ||||||
Balance Sheet Data: | 2016 | 2015 | |||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 74,105 | $ | 106,660 | |||
Restricted cash and marketable securities | 12,794 | 13,506 | |||||
Accounts receivable, net of allowance of $208,780 and $167,411, respectively | 375,352 | 337,330 | |||||
Supplies inventory | 21,980 | 21,406 | |||||
Prepaid and other current assets | 74,565 | 75,771 | |||||
Total current assets | 558,796 | 554,673 | |||||
Property and equipment, net | 204,922 | 189,168 | |||||
Investments in unconsolidated affiliates | 179,056 | 169,170 | |||||
Goodwill | 4,175,008 | 3,970,210 | |||||
Intangible assets, net | 1,679,275 | 1,594,637 | |||||
Other assets | 46,263 | 21,450 | |||||
Total assets | $ | 6,843,320 | $ | 6,499,308 | |||
Liabilities and Equity | |||||||
Current liabilities: | |||||||
Current portion of long-term debt | $ | 20,772 | $ | 20,377 | |||
Accounts payable | 30,721 | 32,561 | |||||
Accrued salaries and benefits | 186,908 | 202,537 | |||||
Accrued interest | 30,400 | 30,480 | |||||
Other accrued liabilities | 92,571 | 119,237 | |||||
Total current liabilities | 361,372 | 405,192 | |||||
Long-term debt | 2,581,043 | 2,357,956 | |||||
Deferred income taxes | 743,447 | 699,498 | |||||
Other long-term liabilities | 119,478 | 96,183 | |||||
Commitments and contingencies | |||||||
Noncontrolling interests – redeemable | 177,845 | 175,732 | |||||
Equity: | |||||||
Preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding | 166,632 | 166,632 | |||||
Common stock, no par value, 120,000 shares authorized, 54,816 and 54,294 shares issued and outstanding, respectively | 1,356,829 | 1,345,418 | |||||
Retained earnings | 853,817 | 781,413 | |||||
Total AmSurg Corp. equity | 2,377,278 | 2,293,463 | |||||
Noncontrolling interests – non-redeemable | 482,857 | 471,284 | |||||
Total equity | 2,860,135 | 2,764,747 | |||||
Total liabilities and equity | $ | 6,843,320 | $ | 6,499,308 | |||
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 9 | ||
August 2, 2016 | ||
AMSURG CORP. Unaudited Selected Consolidated Financial and Operating Data, continued (In thousands) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
Statement of Cash Flow Data: | 2016 | 2015 | 2016 | 2015 | |||||||||||
Cash flows from operating activities: | |||||||||||||||
Net earnings | $ | 103,119 | $ | 90,747 | $ | 187,823 | $ | 159,502 | |||||||
Adjustments to reconcile net earnings to net cash flows provided by operating activities: | |||||||||||||||
Depreciation and amortization | 30,054 | 23,612 | 59,126 | 46,430 | |||||||||||
Amortization of deferred loan costs | 2,139 | 2,081 | 4,279 | 4,155 | |||||||||||
Provision for uncollectibles | 107,606 | 70,515 | 207,046 | 144,514 | |||||||||||
Net (gain) loss on disposals and deconsolidations | (2,595 | ) | 3,035 | (2,595 | ) | 3,258 | |||||||||
Share-based compensation | 7,900 | 3,883 | 15,068 | 7,592 | |||||||||||
Excess tax benefit from share-based compensation | (129 | ) | (216 | ) | (3,734 | ) | (3,533 | ) | |||||||
Deferred income taxes | 14,385 | (635 | ) | 20,987 | 2,699 | ||||||||||
Equity in earnings of unconsolidated affiliates | (7,351 | ) | (3,989 | ) | (13,930 | ) | (6,640 | ) | |||||||
Net change in fair value of contingent consideration | (2,598 | ) | 6,410 | (2,598 | ) | 6,410 | |||||||||
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions: | |||||||||||||||
Accounts receivable | (113,851 | ) | (82,842 | ) | (228,374 | ) | (157,056 | ) | |||||||
Supplies inventory | (234 | ) | (80 | ) | (412 | ) | (110 | ) | |||||||
Prepaid and other current assets | (15,321 | ) | 16,485 | (23,744 | ) | 30,327 | |||||||||
Accounts payable | 2,761 | 1,830 | (3,347 | ) | (696 | ) | |||||||||
Accrued expenses and other liabilities | (17,148 | ) | 20,534 | (28,204 | ) | 12,648 | |||||||||
Other, net | 4,595 | 1,198 | 7,714 | 1,895 | |||||||||||
Net cash flows provided by operating activities | 113,332 | 152,568 | 195,105 | 251,395 | |||||||||||
Cash flows from investing activities: | |||||||||||||||
Acquisitions and related expenses | (278,123 | ) | (69,454 | ) | (281,113 | ) | (196,032 | ) | |||||||
Acquisition of property and equipment | (21,927 | ) | (17,882 | ) | (37,618 | ) | (32,665 | ) | |||||||
Proceeds from sale of interests in surgery centers | 25 | — | 25 | — | |||||||||||
Purchases of marketable securities | (498 | ) | (1,245 | ) | (498 | ) | (1,245 | ) | |||||||
Maturities of marketable securities | 498 | 2,988 | 2,738 | 2,988 | |||||||||||
Other | (7,240 | ) | (1,767 | ) | (8,749 | ) | (1,987 | ) | |||||||
Net cash flows used in investing activities | (307,265 | ) | (87,360 | ) | (325,215 | ) | (228,941 | ) | |||||||
Cash flows from financing activities: | |||||||||||||||
Proceeds from long-term borrowings and revolving credit facility | 300,954 | 5,568 | 317,151 | 7,795 | |||||||||||
Repayment on long-term borrowings and revolving credit facility | (58,431 | ) | (5,075 | ) | (98,763 | ) | (10,288 | ) | |||||||
Distributions to noncontrolling interests | (58,788 | ) | (53,831 | ) | (115,589 | ) | (101,033 | ) | |||||||
Proceeds from issuance of common stock upon exercise of stock options | 174 | 334 | 450 | 2,080 | |||||||||||
Repurchase of common stock | — | — | (5,688 | ) | (3,684 | ) | |||||||||
Other | (1,754 | ) | (2,071 | ) | (6 | ) | 886 | ||||||||
Net cash flows provided by (used in) financing activities | 182,155 | (55,075 | ) | 97,555 | (104,244 | ) | |||||||||
Net increase (decrease) in cash and cash equivalents | (11,778 | ) | 10,133 | (32,555 | ) | (81,790 | ) | ||||||||
Cash and cash equivalents, beginning of period | 85,883 | 116,156 | 106,660 | 208,079 | |||||||||||
Cash and cash equivalents, end of period | $ | 74,105 | $ | 126,289 | $ | 74,105 | $ | 126,289 | |||||||
-MORE-
AMSG Reports Second-Quarter Results | ||
Page 10 | ||
August 2, 2016 | ||
AMSURG CORP.
Footnotes to Reconciliations of Non-GAAP Measures to GAAP Measures
(1) | We believe the calculation of adjusted net earnings from continuing operations per diluted share attributable to AmSurg Corp. common shareholders provides a better measure of our ongoing performance and provides better comparability to prior periods because it excludes discontinued operations, the gains or loss from deconsolidations, which are non-cash in nature, transaction costs, including associated debt extinguishment costs and deferred financing write-off, and acquisition-related amortization expense, changes in contingent purchase price consideration and share-based compensation expense. Adjusted net earnings from continuing operations per diluted share attributable to AmSurg Corp. common shareholders should not be considered as a measure of financial performance under accounting principles generally accepted in the United States, and the items excluded from it is a significant component in understanding and assessing financial performance. Because adjusted net earnings from continuing operations per diluted share attributable to AmSurg Corp. common shareholders is not a measurement determined in accordance with accounting principles generally accepted in the United States and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. For purposes of calculating adjusted earnings per share, we utilize the if-converted method to determine the number of diluted shares outstanding. In periods where utilizing the if-converted method is anti-dilutive, the mandatory convertible preferred stock will not be included in the calculation of diluted shares outstanding. |
(2) | We define Adjusted EBITDA of AmSurg as earnings before interest expense, net, income taxes, depreciation, amortization, share-based compensation, transaction costs, changes in contingent purchase price consideration, gain or loss on deconsolidations and discontinued operations. Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA is an analytical indicator used by management and the health care industry to evaluate company performance, allocate resources and measure leverage and debt service capacity. Adjusted EBITDA should not be considered in isolation or as an alternative to net income, cash flows from operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies. Net earnings from continuing operations attributable to AmSurg Corp. common shareholders is the financial measure calculated and presented in accordance with generally accepted accounting principles that is most comparable to Adjusted EBITDA as defined. |
-END-